Washington, District of Columbia 20007

  • Colorectal Cancer


RATIONALE: Diagnostic procedures, such as radionuclide imaging using bispecific antibody, may help find colorectal cancer cells and learn the extent of disease. PURPOSE: This phase I trial is studying how well a bispecific antibody works in finding tumor cells in patients with colorectal cancer.

Study summary:

OBJECTIVES: - Assess the pharmacokinetics and tissue distribution of anti-CEA x anti-HSG bispecific monoclonal antibody TF2 in patients with colorectal cancer. OUTLINE: This is a multicenter study. Patients receive iodine I 131-labeled anti-CEA x anti-HSG bispecific monoclonal antibody TF2 (^131I-TF2) IV over 10-20 minutes on day 1. Patients also undergo whole-body external scintigraphy at various times during the study. Blood samples are collected at baseline and periodically after ^131I-TF2 infusion for pharmacokinetic studies and ^131I-TF2 biodistribution by ELISA and radioactivity measurements.


DISEASE CHARACTERISTICS: - Histologically confirmed colorectal cancer - Radiological documentation of disease is preferred, but not required PATIENT CHARACTERISTICS: - Karnofsky performance status 70-100% - Life expectancy ≥ 3 months - WBC ≥ 3,000/mm³ - Neutrophil count ≥ 1,500/mm³ - Platelet count ≥ 100,000/mm³ - Serum creatinine normal - Bilirubin ≤ 1.5 times upper limit of normal (ULN) - AST/ALT < 2 times ULN - Not pregnant or nursing - Fertile patients must use effective contraception during and for 1 month after completion of study therapy - No medical conditions that might prevent full participation in protocol-required testing or follow-up - No institutionalized patients (e.g., in prisons or mental health institutions) PRIOR CONCURRENT THERAPY: - No concurrent chemotherapy or treatments that would compromise the safety and efficacy of protocol assessments



Primary Contact:

Principal Investigator
Aiwu R. He, MD
Lombardi Cancer Research Center

Backup Contact:


Location Contact:

Washington, District of Columbia 20007
United States

Clinical Trials Office - Lombardi Comprehensive Cancer Center
Phone: 202-444-0381

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: November 27, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.